Cabaletta Bio

Cabaletta Bio

Associate Project Manager / Project Manager - Clinical Program Management (Remote)

US | $97K - $179K

Apply for job

Company information

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Linkedin Icon
51-200 employees
Biotechnology, Therapeutics, Pharmaceuticals, Healthcare, Genetics
Public Company
Last round: Jun 17, 2023
Last round: US$ 87.0M
Philadelphia, Pennsylvania
Company Specialties:
cell therapy, biotech, immunology, autoimmune, and rheumatology